Oxonic acid potassium salt selectively and competitively inhibits the activity of uricase, effectively elevating uric acid levels in vivo. Oxonic acid potassium salt inhibits the phosphorylation of 5-fluorouracil (5-FU) to 5-fluorouridine-5'-monophosphate[1-2]. Oxonic acid potassium salt can be used to establish animal models of hyperuricemia and serves as an auxiliary tool in cancer research[3-4].
In vivo, treatment of Kunming mice with Oxonic acid potassium salt (350mg/kg/day) combined with Hypoxanthine (450mg/kg/day) via intraperitoneal injection and oral gavage for 8 consecutive weeks induced a chronic hyperuricemia model, Oxonic acid potassium salt significantly led to left ventricular anterior wall thickening, myocardial structural disorganization, increased cardiac mass, and was accompanied by complications such as renal enlargement and renal tubule dilation[5]. Treatment of Kunming mice with Oxonic acid potassium salt (350mg/kg/day) combined with Hypoxanthine (450mg/kg/day) via intraperitoneal injection and oral gavage for 1 consecutive week induced a hyperuricemia model, Oxonic acid potassium salt significantly decrease in polyamine levels in cardiomyocytes and upregulation of the protein expression of the key polyamine synthesis enzyme ODC1 and the metabolic enzyme SAT1, leading to cardiomyocyte injury[6].
References:
[1] Zhang N, Zhang B, Chen X, et al. Effects and mechanisms of Polygonati Rhizoma polysaccharide on potassium oxonate and hypoxanthine-induced hyperuricemia in mice. Int J Biol Macromol. 2024 Sep 13;280(Pt 1):135550.
[2] Yamashita T, Ueda Y, Fuji N, et al. Potassium oxonate, an enzyme inhibitor compounded in S-1, reduces the suppression of antitumor immunity induced by 5-fluorouracil. Cancer Chemother Pharmacol. 2006 Aug;58(2):183-8.
[3] Tian J, Wang B, Xie B, et al. Pyroptosis inhibition alleviates potassium oxonate- and monosodium urate-induced gouty arthritis in mice. Mod Rheumatol. 2022 Jan 5;32(1):221-230.
[4] Yoshisue K, Hironaga K, Yamaguchi S, et al. Reduction of 5-fluorouracil (5-FU) gastrointestinal (GI) toxicity resulting from the protection of thymidylate synthase (TS) in GI tissue by repeated simultaneous administration of potassium oxonate (Oxo) in rats. Cancer Chemother Pharmacol. 2000;46(1):51-6.
[5] Lin C, Zheng Q, Li Y, et al. Assessment of the influence on left ventricle by potassium oxonate and hypoxanthine-induced chronic hyperuricemia. Exp Biol Med (Maywood). 2023 Jan;248(2):165-174.
[6] Lin C, Zheng Q, Yu H, et al. Uric acid-induced cardiomyocytic polyamines' insufficience: a potential mechanism mediates cardiomyocytic injury. Front Endocrinol (Lausanne). 2025 Apr 7;16:1504614.
Oxonic acid potassium salt能够选择性地、竞争性地抑制尿酸酶的活性，能有效导致体内尿酸水平升高。Oxonic acid potassium salt抑制5-氟尿嘧啶（5-FU）磷酸化为5-氟尿苷-5'-单磷酸酯的过程[1-2]。Oxonic acid potassium salt可用构建高尿酸血症动物模型，和作为肿瘤研究的辅助工具[3-4]。
在体内，Oxonic acid potassium salt（350mg/kg/天）联合Hypoxanthine（450mg/kg/天）腹腔注射及灌胃处理昆明小鼠（连续8周），Oxonic acid potassium salt诱导的慢性高尿酸血症模型显著引起左心室前壁增厚、心肌结构紊乱及心脏质量增加，并伴随肾脏肿大、肾小管扩张等并发症[5]。Oxonic acid potassium salt（350mg/kg/天）联合Hypoxanthine（450mg/kg/天）腹腔注射及灌胃处理昆明小鼠（连续1周），Oxonic acid potassium salt诱导的高尿酸血症模型导致心肌细胞内多胺水平显著降低，并上调多胺合成关键酶ODC1和代谢酶SAT1的蛋白表达，导致心肌细胞损伤[6]。